Proceedings of the 40th Annual General Meeting of the Company held on today i.e. 18th July, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals held its 40th AGM on 18th July 2025 via video conferencing, with a brief delay due to a technical glitch; the meeting ran from 3:30 PM to 4:37 PM. The Chairman shared the company's 40-year journey and FY2024-25 performance, highlighting the reorganisation of the pharma division into two focused units called NOVA and ZORA, a strategic tie-up with NIMHANS, and the wellness division's performance, along with emphasis on innovation, AI integration, and sustainability. Six resolutions were passed, including adoption of audited financials, declaration of a ₹18 per share dividend (180% on face value of ₹10), re-appointment of Shri Ashish U. Bhuta as Director retiring by rotation and as Chairman & Managing Director, appointment of Secretarial Auditors for a five-year term, and ratification of Cost Auditor remuneration for FY2025-26. Statutory and Secretarial Auditor reports contained no adverse qualifications, and the meeting had the required quorum throughout. Voting results will be submitted to the stock exchanges separately within the prescribed timeline.
The 180% dividend declaration reflects strong cash generation and is a positive signal for income-focused shareholders. Re-appointment of the existing CMD ensures management continuity, while the pharma division restructuring into NOVA and ZORA plus the NIMHANS tie-up signals an active growth strategy, which could support long-term shareholder value.